ArticleAdvanced biomedical research2026
Bioinformatics Analysis of the miR-15 Family Members and Their Potential Target Genes in Breast Cancer Progression.
Article in Advanced biomedical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most common cancer in women and the second most frequent cancer worldwide. Changes in miRNA levels are associated with various diseases, including cancer, making them ideal non-invasive biomarkers for diagnosis, prognosis, and treatment. Bioinformatics advancements have enabled the prediction of miRNAs and their target genes. This study aimed to analyze the miR-15 family (miR-15a, miR-15b, miR-16-1, miR-16-2, miR-195, and miR-497) to predict their target genes and evaluate their role in breast cancer progression. Materials and Methods: Expression levels of the miR-15 family were evaluated in healthy and cancerous breast tissues using the OncomiR database. Target genes involved in breast cancer-related pathways were identified through the DIANA TOOLS-mirPath v.3 database. Algorithms from online databases such as TargetScan, miRWalk 2.0, and RNAhybrid were used to rank the genes. Genes with the highest scores were analyzed for their functional roles using the DAVID database. Results: Analysis of cell adhesion, TGF-beta, and P53 pathways identified seven genes (IGF1R, PVRL1, SMAD7, CCND2, CCND1, SESN1, and CCNE1) as common targets of miR-15a-5p, miR-15b-5p, miR-195-5p, and miR-497-5p. Additionally, CCNG2 was identified as an exclusive target of miR-16-1-3p. These genes were enriched in pathways associated with cell adhesion, apoptosis, and key cancer-related signaling networks. Conclusion: Members of the miR-15 family may serve as biomarkers for breast cancer by targeting genes involved in cell adhesion, apoptosis, and pathways such as TGF-β and P53. Further clinical and laboratory studies are recommended to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.